HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Public ClinicalTrials.gov record NCT04904588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Study identification
- NCT ID
- NCT04904588
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- Busulfan Drug
- Fludarabine Drug
- Total-body irradiation Radiation
- Cyclophosphamide Drug
- Melphalan Drug
- PBSC Hematopoietic Stem Cell Transplantation (HSCT) Procedure
- Bone Marrow Hematopoietic Stem Cell Transplantation Procedure
- Post-transplant Cyclophosphamide Drug
- Mesna Drug
- Tacrolimus Drug
- Mycophenolate Mofetil Drug
- Patient-Reported Outcomes Other
Drug · Radiation · Procedure + 1 more
Eligibility (public fields only)
- Age range
- 1 Year and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2021
- Primary completion
- Jul 31, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Mar 17, 2026
2021 – 2026
United States locations
- U.S. sites
- 39
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| University of Florida Health Shands Hospital | Gainesville | Florida | 32610 | — |
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| Emory University Medical Center | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Medical Center - Mott Children's Hospita | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Washington University/Barnes Jewish Hospital | St Louis | Missouri | 63110 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Cincinnati Children's Hospital | Cincinnati | Ohio | 45229 | — |
| Ohio State Medical Center, James Cancer Center | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29407 | — |
| TriStar BMT | Nashville | Tennessee | 37203 | — |
| TriStar Medical Group Children's Specialists | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| St. David's South Austin Medical Center | Austin | Texas | 78704 | — |
| -Baylor College of Medicine - Texas Children's Hospital and Houston Methodist | Houston | Texas | 77030 | — |
| Texas Transplant Institute | San Antonio | Texas | 37203 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
| University of Wisconsin Hospital and Clinic | Madison | Wisconsin | 53792 | — |
| Froedtert & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04904588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04904588 live on ClinicalTrials.gov.